Skip to main content

Table 1 Clinical characteristics of patients at baseline

From: Serum interleukin-6 is an indicator for severity in 901 patients with SARS-CoV-2 infection: a cohort study

Parameters Entire cohort (N = 901) Common (n = 366) Severe (n = 411) Critical (n = 124) P value
Age, years (median, IQR) 60.0 (49.0–69.0) 54.0 (42.8–62.0) 64.0 (52.0–71.0) 68.5 (58.0–78.0) < 0.001
Sex-n, % 0.015
 Male 435 (48.3) 161 (44.0) 201 (48.9) 73 (58.9)  
 Female 466 (51.7) 205 (56.0) 210 (51.1) 51 (41.1)  
Coexisting disorders-n, % 509 (56.5) 171 (46.7) 245 (59.6) 93 (75.0) < 0.001
 Hypertension 289 (32.1) 82 (22.4) 149 (36.3) 58 (46.8) < 0.001
 Diabetes mellitus 126 (14.0) 38 (10.4) 57 (13.9) 31 (25.0) < 0.001
 Chronic obstructive lung disease 17 (1.9) 3 (0.8) 7 (1.7) 7 (5.6) < 0.001
 Hemorrhagic or ischemic stroke 38 (4.2) 6 (1.6) 15 (3.6) 17 (13.7) < 0.001
 History of tuberculosis 13 (1.4) 4 (1.1) 5 (1.2) 4 (3.2) 0.002
 Autoimmune diseases 10 (1.1) 4 (1.1) 4 (1.0) 2 (1.6) 0.49
 Chronic kidney disease 13 (1.4) 0 (0) 3 (0.7) 10 (8.1) < 0.001
 Malignancies 22 (2.4) 8 (2.2) 13 (3.2) 1 (0.8) 0.30
 Coronary artery disease 73 (8.1) 18 (4.9) 37 (9.0) 18 (14.5) 0.002
 Chronic dialysis 7 (0.8) 0 (0) 2 (0.5) 5 (4.0) < 0.001
Baseline IL-6 < 0.001
 Normal-n, % 708 (78.6) 347 (94.8) 329 (80.0) 32 (25.8)  
 Elevateda-n, % 193 (21.4) 19 (5.2) 82 (20.0) 92 (74.2)  
Tocilizumab used-n, % 16 (1.8) 4 (1.1) 7 (1.7) 5 (4) 0.39
Outcomesb-n, % < 0.001
 Cured/discharged 683 (75.8) 290 (79.2) 340 (82.7) 53 (42.7) < 0.001
 Continued hospitalization 193 (21.4) 76 (20.8) 70 (17.0) 47 (37.9) < 0.001
 Death 24 (2.7) 0 (0) 0 (0) 24 (19.4) < 0.001
  1. aHigher than upper limit of normal
  2. b1 missing data in the severe group